Cytokinetics, Incorporated (CYTK)
| Market Cap | 3.77B |
| Revenue (ttm) | 19.22M |
| Net Income (ttm) | -615.26M |
| Shares Out | 119.43M |
| EPS (ttm) | -5.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,275 |
| Open | 31.29 |
| Previous Close | 31.31 |
| Day's Range | 30.78 - 31.72 |
| 52-Week Range | 29.31 - 61.38 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 75.65 (+139.78%) |
| Earnings Date | May 6, 2025 |
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo... [Read more]
Financial Performance
In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is $75.65, which is an increase of 139.78% from the latest price.
News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275...
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: C...
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering
Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted REMS. Positive phase 3 MAPLE-HCM study results show aficamten significantly ou...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Cytokinetics' heart disease drug meets main goal in late-stage study
Cytokinetics said on Tuesday its experimental heart disease drug met the main goal in a late-stage study.
Cytokinetics Announces Positive Topline Results From MAPLE-HCM
Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., M...
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the C...
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart ...
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the C...
Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 ...
Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook
The FDA extended aficamten's review by three months for REMS safety program finalization, causing Cytokinetics' stock to drop over 11%. The REMS requirement is expected and does not indicate fundament...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the C...
Cytokinetics, Incorporated (CYTK) Q1 2025 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Affairs Robert Blum - President &...
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES , May 6, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cytokinetics, Incorp...
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ...
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the Compan...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated ("Cytokinetics" or "the C...